Abstract:IMPORTANCE The efficacy of folic acid therapy on renal outcomes has not been previously investigated in populations without folic acid fortification.OBJECTIVE To test whether treatment with enalapril and folic acid is more effective in slowing renal function decline than enalapril alone across a spectrum of renal function at baseline from normal to moderate chronic kidney disease (CKD) among Chinese adults with hypertension.DESIGN, SETTING, AND PARTICIPANTS In this substudy of eligible China Stroke Primary Prevention Trial (CSPPT), 15 104 participants with an estimated glomerular filtration rate (eGFR) 30 mL/min/1.73m(2) or greater, including 1671 patients with CKD, were recruited from 20 communities in Jiangsu province in China.INTERVENTIONS Participants were randomized to receive a single tablet daily containing 10mg enalapril and 0.8mg folic acid (n = 7545) or 10mg enalapril alone (n = 7559).MAIN OUTCOMES AND MEASURES The primary outcomewas the progression of CKD, defined as a decrease in eGFR of 30% or more and to a level of less than 60 mL/min/1.73m(2) if the baseline eGFR was 60 mL/min/1.73m(2) or more, or a decrease in eGFR of 50% or more if the baseline eGFR was less than 60 mL/min/1.73m(2); or end-stage renal disease. Secondary outcomes included a composite of the primary outcome and all-cause death, rapid decline in renal function, and rate of eGFR decline.RESULTS Overall, 15 104 Chinese adults with a mean (range) age of 60 (45-75) years were recruited; median follow-up was 4.4 years. There were 164 and 132 primary events in the enalapril group and the enalapril-folic acid group, respectively. Compared with the enalapril group, the enalapril-folic acid group had a 21% reduction in the odds of the primary event (odds ratio [OR], 0.79; 95% CI, 0.62-1.00) and a slower rate of eGFR decline (1.28% vs 1.42% per year; P =.02). Among the participants with CKD at baseline, folic acid therapy resulted in a significant reduction in the risks for the primary event (OR, 0.44; 95% CI, 0.26-0.75), rapid decline in renal function (OR, 0.67; 95% CI, 0.47-0.96) and the composite event (OR, 0.62; 95% CI, 0.43-0.90), and a 44% slower decline in renal function (0.96% vs 1.72% per year, P <.001). Among those without CKD at baseline, there was no between-group difference in the primary end point.CONCLUSIONS AND RELEVANCE Enalapril-folic acid therapy, compared with enalapril alone, can significantly delay the progression of CKD among patients with mild-to-moderate CKD.

Pharmacokinetics and Food Effect of Enalapril Maleate/Folic Acid Tablets in Healthy Chinese Volunteers: A Phase I, Randomized, Open-label, Single- and Multiple-dose Study

Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects

Effects of combined enalapril and folic acid therapy on the serum uric acid levels in hypertensive patients: a multicenter, randomized, double-blind, parallel-controlled clinical trial

Pharmacokinetic study of amlodipine besylate and folic acid tablet in Chinese healthy volunteers

Pharmacokinetics and Safety of Pitavastatin Calcium Tablets in Chinese Healthy Volunteers after a Single Oral Dose Administration

Efficacy Of Folic Acid Therapy On The Progression Of Chronic Kidney Disease The Renal Substudy Of The China Stroke Primary Prevention Trial

Effects of Folic Acid Therapy on the New-Onset Proteinuria in Chinese Hypertensive Patients: A Post Hoc Analysis of the Renal Substudy of CSPPT (china Stroke Primary Prevention Trial).

Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Chinese Hypertensive Patients: a Post-Marketing Double-Blind Randomized Controlled Trial

[The Effect of Baseline Homocysteine Level on the Efficacy of Enalapril Maleate and Folic Acid Tablet in Lowering Blood Pressure and Plasma Homocysteine].

Bioequivalence and Food Effect Assessment of Eltrombopag Olamine Tablets in Healthy Chinese Subjects: An Open, Randomized, Single‐Dose, and Two‐Period Crossover Study

Effects of Food and Multiple‐dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained‐release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers

Bioequivalence Study of Atenolol Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions

Effect of Dining on the Pharmacokinetics of Losartan

Effects of enalapril folic acid combined with levamlodipine on incidence of cardiovascular and cerebrovascular events in patients with essential hypertension

Effect of Eating on Pharmacokinetics of Ethanesulfonic Acid Levofloxacin Tablets

Effects of Food and Gender on Pharmacokinetics of Rosuvastatin in a Chinese Population Based on 4 Bioequivalence Studies

Efficacy of Fixed Vs. Free Combination of Enalapril-Folic Acid Tablet in Controlling Elevated Plasma Homocysteine in Patients with H-type Hypertension

Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults: do methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms affect therapeutic responses?

Effect of Folic Acid Intervention on ALT Concentration in Hypertensives Without Known Hepatic Disease: a Randomized, Double-Blind, Controlled Trial

Effect of Enalapril on Plasma Homocysteine Levels in Patients with Essential Hypertension

Pharmacokinetic and Bioequivalence Evaluation of Dihydroxyaluminum Aminoacetate, Heavy Magnesium Carbonate, and Aspirin Tablets in Healthy Chinese Subjects in the Fasting and Postprandial Conditions